News | March 05, 2024
Biocon Biologics secures Canada market entry date for YESAFILI
This agreement paves the way for the introduction of YESAFILI into the Canadian market
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
BHL will undertake the development and supply of these molecules
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Subscribe To Our Newsletter & Stay Updated
